CD19 and Autoimmunity: The presence of pathogenic plasmablasts with low CD20 and high CD19 expression has been reported in RA, SLE, MS, and other autoimmune conditions, and this B cell population has been demonstrated to be refractory to the anti-CD20–mediated B cell depletion (7–9)